Indication: Squamous Cell Carcinoma
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)
Sub-indication: Head and Neck Cancer
Study Type: Drug Study
Principal Investigator: Aaron Spalding, M.D.Norton Cancer Institute
Sponsor: Sponsor: Debiopharm International S.A
Learn more at ClinicalTrials.gov
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org